 |
인쇄하기
취소
|
MSD Korea, Daewoong seeking strategic alliance for Januvia
MSD Korea and Daewoong Pharm have recently agreed to jointly market Januvia (sitagliptin phosphate) under their second strategic alliance following Fosamax Plus last March.
Approved by the Korea Food and Drug Administration last October, Januvia is an oral diabetes medication in a new class of drugs known as DPP-4 inhibitors. Januvia blocks an enzyme called dipeptidyl peptidase 4, or DPP-4, ...
Approved by the Korea Food and Drug Administration last October, Januvia is an oral diabetes medication in a new class of drugs known as DPP-4 inhibitors. Januvia blocks an enzyme called dipeptidyl peptidase 4, or DPP-4, ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.